NewsRoom Articles - Page 90 of 154 - PsychedelicNewsWire (PNW)

FridayJul 23, 2021 2:00 pm

Study Finds That Ketamine, Psilocybin Improve Attention in Rodent Models

A new study has found that low doses of ketamine and psilocybin can boost attention and intensify motivation associated with food in low-performing rodents. Guy Higgins, lead author of the study and CEO of InterVivo Solutions, the company that carried out the study, stated that interest in the pharmacological effects of low doses of NMDA antagonists is what led the research team to study psilocybin and ketamine. Anecdotal reports on micro-dosing psychedelics indicate that the substances improve cognitive function and mood in humans. However, very few appropriately controlled trials have been conducted in this field. Higgins explained that the objective…

ThursdayJul 22, 2021 2:45 pm

Researchers Call for Re-evaluation of Specialized Nerve Treatments for Chronic Pain

A study conducted by researchers from the Lawson Health Research Institute evaluated the use of specialized treatments for chronic pain and their effect on opioid prescriptions and the use of health care. A recent report by the “Toronto Star” stated that since 2011, the Ontario Health Insurance Plan had been billed more than $400 million for nerve block procedures. Paravertebral blocks (PVBs) are types of procedures classified under nerve blocks. They involve injecting drugs around the nerves where those nerves exit the spine’s bones at different locations depending on the chronic pain a patient is experiencing. The efficacy of paravertebral…

ThursdayJul 22, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event

Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the…

WednesdayJul 21, 2021 3:00 pm

Can Psychedelics Be Used to Heal Moral Injuries?

Moral injury is the social, behavioral, psychological and spiritual distress that occurs in response to witnessing a behavior or acting in a way that doesn’t align with an individual’s moral beliefs and values. Researchers assert that moral injuries are not psychiatric diagnoses but may manifest as self-handicapping and avoidant behaviors, thoughts of systemic failures and personal regret, sadness, disgust, anger, shame and guilt. These injuries have been linked to considerable impairment in occupational, health and relational functioning and are considered to be less normative and more syndromal moral pain. PTSD and moral injuries often co-exist, but researchers note that while…

TuesdayJul 20, 2021 3:15 pm

Psychedelic Substances May Decrease Criminal Behavior

A study conducted by researchers from the University of Alabama in collaboration with the University of British Columbia Okanagan Campus proposes that psychedelic substances such as mescaline, LSD and psilocybin mushrooms may decrease criminal offenses. The study, which was co-authored by Zach Walsh, an associate professor in the Department of Psychology at UBC Okanagan, discovered that psychedelic substances were linked to a reduced likelihood of antisocial criminal behavior. Walsh stated that the team’s discovery adds to a growing body of research which suggests that the use of psychedelics may have a positive impact on decreasing antisocial behavior; he noted that…

TuesdayJul 20, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces New Board Appointment

Former head of psychiatry products at FDA joins Cybin team. Laughren will help company plot its regulatory pathway as it studies and develops psychedelic medicines. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is making strategic moves as it progresses with pre-clinical and clinical trials. One of those steps includes the company’s recent announcement that Thomas Laughren is joining Cybin’s clinical advisory board (https://ibn.fm/q0abz). A medical doctor who served as the director of the U.S. Food and Drug Administration’s division of psychiatry products for nearly three decades, Laughren will help the company plot its regulatory…

MondayJul 19, 2021 3:00 pm

Could DMT Sweep Existing Treatments for Depression Aside?

Since research on psychedelics was revived in the 2000s, prompted by the easing of the regulations that govern the substances, a lot of studies have shown that drugs such as LSD and psilocybin possess great therapeutic potential and can be used to treat conditions such as depression, anxiety and addiction. These discoveries have led to the creation of companies that are focused on psychedelic therapy and that are working on finding ways in which these substances can be used in lieu of conventional medicine. Among these companies is Small Pharma, a neuropharmaceutical firm based in the United Kingdom, which is…

MondayJul 19, 2021 11:21 am

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

XPhyto partners with AGORA t to grow its brand and overall market share The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 AGORA is known for its online marketing, conferences, broadcasting and investor relations services Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp…

MondayJul 19, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Acquisition Leads to Milestone Achievement, Positive Pre-Clinical Results

CYBN subsidiary Adelia Therapeutics has reached earn-out milestones. Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules. Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). "These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s…

FridayJul 16, 2021 3:00 pm

International Study Finds That Ayahuasca Improves Depression, Anxiety Symptoms

Research has found that psychedelics possess therapeutic benefits that can be used to manage various mental health conditions, including anxiety and depression. Until recently, most studies conducted on these substances had been small scale. The Global Ayahuasca Project, which focused on ayahuasca, is the largest cross-sectional study on the use of ayahuasca to date. Ayahuasca is a pan-Amazonian (South American) psychedelic brew made from the Banisteriopsis caapi vine, which is utilized in ceremonial spiritual medicine as well as socially. The study, which was carried out between 2017–2020, found a connection between improvements in the symptoms of disorders such as depression…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000